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a  b  s  t  r  a  c  t
Background:  Brain-derived  neurotrophic  factor  (BDNF)  is  a neurotrophin  involved  in  neurogenesis  and
synaptic  plasticity  in the  central  nervous  system,  especially  in  the hippocampus,  and  has  been  implicated
in  the  pathophysiology  of  several  neuropsychiatric  disorders.  Its  Val66Met  polymorphism  (refSNP  Cluster
Report: rs6265)  is a  functionally  relevant  single  nucleotide  polymorphism  affecting  the  secretion  of  BDNF
and  is  implicated  in differences  in hippocampal  volumes.
Methods:  This  is a systematic  meta-analytical  review  of  ﬁndings  from  imaging  genetic  studies  on  the
impact  of the rs6265  SNP  on  hippocampal  volumes  in  neuropsychiatric  patients  with  major  depressive
disorder,  anxiety,  bipolar  disorder  or schizophrenia.
Results:  The  overall  sample  size  of 18  independent  clinical  cohorts  comprised  1695 patients.  Our  results
indicated  no  signiﬁcant  association  of  left (Hedge’s  g = 0.08,  p =  0.12),  right  (g = 0.07,  p  = 0.22)  or bilateral
(g  =  0.07,  p = 0.16)  hippocampal  volumes  with  BDNF  rs6265  in  neuropsychiatric  patients.  There  was  no
evidence  for  a publication  bias  or any  demographic,  clinical,  or methodological  moderating  effects.





sample  had  signiﬁcantly  smaller  hippocampal  volumes  than  the  healthy  control  sample  with the  same
allele.  The  magnitude  of these  effects  did not  differ  between  the  two  genotypes.
Conclusion:  This  meta-analysis  suggests  that  there  is  no association  between  this  BDNF  polymorphism
and  hippocampal  volumes.  For  each  BDNF  genotype,  the  hippocampal  volumes  were  signiﬁcantly  lower
in neuropsychiatric  patients  than  in  healthy  controls.©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
Hippocampal atrophy is a common characteristic of neuropsy-
hiatric disorders, such as major depressive disorder, bipolar
isorder, anxiety disorders and schizophrenia (Buehlmann et al.,
010; Fusar-Poli et al., 2007; Geuze et al., 2005; Kempton et al.,
011; Shepherd et al., 2012). The hippocampus has been intensely
tudied, as it is involved in learning and memory-dependent pro-
esses (Kandel, 2001; McDonald and Hong, 2013; Preston and
ichenbaum, 2013) and due to the occurrence of cognitive impair-
ent in neuropsychiatric disorders (Bora et al., 2010; Bourne
t al., 2013; Fusar-Poli et al., 2012; Schaefer et al., 2013; Snyder,
013).
Brain-derived neurotrophic factor (BDNF) is a widely investi-
ated marker in neuropsychiatric disorders and may  be important
n the pathophysiology of depression (Buchmann et al., 2013;
arege et al., 2002; Lang and Borgwardt, 2013; Shimizu et al., 2003),
ipolar disorder (Cunha et al., 2006) and schizophrenia (Niitsu et al.,
014; Numata et al., 2006). BDNF protein is involved in neuro-
enesis and neuroplasticity in the brain. Proper BDNF signalling
equires both pro-BDNF and mature BDNF. BDNF concentrations
an be measured in serum, plasma or whole blood. These concen-
rations are highly correlated with those in cerebrospinal ﬂuid,
s BDNF crosses the blood-brain barrier (Pan et al., 1998; Pillai
t al., 2010). Several meta-analyses have shown that there may
e a correlation between low BDNF levels and the emergence of
epression (Fernandes et al., 2014; Molendijk et al., 2014), bipolar
isorder (Fernandes et al., 2014, 2011; Lin, 2009) and schizophrenia
Fernandes et al., 2014; Green et al., 2011). The critical role of BDNF
n neuropsychiatric diseases is further reﬂected by the fact that its
evel can be increased by neuropsychiatric medications, such as
ntidepressants, mood stabilisers and antipsychotics (Choi et al.,
006; Dmitrzak-Weglarz et al., 2008; El-Hage et al., 2014; Grande
t al., 2014; Hong et al., 2003; Perkovic et al., 2014; Ricken et al.,
013; Rybakowski et al., 2005; Tsai et al., 2003; Xu et al., 2010; Zai
t al., 2012; Zou et al., 2010).
The single nucleotide polymorphism (SNP) Val66Met, also
nown as G189A or rs6265, represents substitution of a valine (Val)
y a methionine (Met) at codon 66. This substitution in the pro-
egion of BDNF modiﬁes sorting of the protein and its availability
n the synaptic cleft. Met/Met transgenic mice exhibit less activity-
ependent BDNF, with smaller hippocampal volumes, decreased
omplexity of the dendritic arbor of hippocampal neurons (Chen
t al., 2004, 2006; Ninan et al., 2010; Egan et al., 2003) and
mpaired synaptic plasticity, as indicated by a decrease in NMDA
eceptor-dependent long-term depression and long-term poten-
iation (Ninan et al., 2010). Several studies have demonstrated
n association between rs6265 polymorphism and neuropsychi-
tric disorders (e.g. Chen et al., 2008; Gratacòs et al., 2007; Lohoff
t al., 2005; Sklar et al., 2002), although just as many have found
o effect (e.g. Frustaci et al., 2008; González-Castro et al., 2014;
anazawa et al., 2007; Verhagen et al., 2008). However, these asso-
iation studies may  indicate that the Met  allele is protective for
ipolar disorder, but is a risk allele for depression and schizophre-
ia. More speciﬁcally, several studies have investigated the effect of
his BDNF polymorphism on brain volumes of patients with depres-
ion, bipolar disorder or schizophrenia (Aas et al., 2013; Agartz
t al., 2006; Chepenik et al., 2009; Cole et al., 2011; Dutt et al.,
009; Frodl et al., 2007; Gonul et al., 2011; Gruber et al., 2012; Ho . . . . .  . . .  . .  . . .  . .  . . .  . . . . .  . .  . . . . . . .  .  . . . . . . .  . . . . . .  .  . . . .  . . . . .  .  . . .  .  .  .  . . . . . . . . . .  115
et al., 2006, 2007; Jessen et al., 2009; Kanellopoulos et al., 2011;
Koolschijn et al., 2010; Molendijk et al., 2014; Smith et al., 2012;
Stein et al., 2012; Szeszko et al., 2005; Takahashi et al., 2008). Many
of these studies have focussed on the hippocampus, where BDNF
has been shown to play a role in normal learning and memory
(Baj et al., 2013; Cunha et al., 2010) and learning- and memory-
dependent deﬁcits in neuropsychiatric disorders (Baig et al., 2010;
Egan et al., 2003; Lau et al., 2010; Molendijk et al., 2012b; Ninan,
2014) may  be associated with declines in hippocampal volume.
Two previous meta-analyses have investigated the association of
BDNF rs6265 and hippocampal volumes using MRI  techniques in a
neuropsychiatric patient sample (Kambeitz et al., 2012; Molendijk
et al., 2012a). Both studies reported smaller hippocampal volumes
for Met-carriers than for Val/Val homozygotes, but the differences
were non-signiﬁcant. This is in line with our recently published
meta-analysis of healthy individuals that did not indicate a sig-
niﬁcant association between the SNP and hippocampal volumes
(Harrisberger et al., 2014). In contrast, studies of the effect of the
BDNF val66met in major depressive disorder and psychosis found
that the status of Met-carrier and exposure to childhood trauma
have an interactive effect on hippocampus volume (Aas et al., 2013;
Carballedo et al., 2013). The available meta-analyses addressing
hippocampal volumes in neuropsychiatric patients genotyped for
SNP rs6265 included relatively small samples and yielded incon-
clusive results (Kambeitz et al., 2012; Molendijk et al., 2012a).
To overcome this lack of knowledge and to reconcile inconsis-
tencies across individual studies, we  present here the ﬁrst robust
quantitative meta-analysis of BDNF rs6265 effects on hippocam-
pal volumes in different neuropsychiatric disorders. In the present
meta-analysis of a total of 1695 individuals, we  sought to explore a
putative association between hippocampal volumes and the BDNF
polymorphism in neuropsychiatric disorders, such as major depres-
sive disorder, bipolar disorder, anxiety disorders or schizophrenia.
Furthermore, we  investigated whether the Met  allele can be des-
ignated as a “risk” or as a “protective” allele in relation to the
hippocampus volume. We therefore examined for the ﬁrst time the
risk that patients had smaller hippocampal volumes than healthy
controls, both for Val/Val homozygote individuals and for Met car-
riers.
2. Materials and methods
We  followed the “Preferred Reporting Items for Systematic
Reviews and Meta-Analyses” (PRISMA) guidelines (Moher et al.,
2010).
2.1. Literature search strategy and selection of studies
The electronic databases PubMed and Embase were searched,
with consideration of all publications with the following search
terms: “BDNF Val66Met” AND “MRI” and “rs6265” AND “MRI” pub-
lished until the end of May  2014. In addition, the reference lists of
the included articles were reviewed. This resulted in 79 publica-
tions, from which the abstracts were screened (more information
is presented in Fig. 1). In this meta-analysis, we included stud-
ies addressing the relation between hippocampal volumes and
the SNP rs6265 in neuropsychiatric patients using the follow-
ing inclusion criteria: (a) published in a peer-reviewed journal,
(b) reporting a relation between the SNP rs6265 and structural






























mFig. 1. Flow chart of the search strateg
agnetic resonance imaging (sMRI), and (c) showing hippocampal
ata. A total of 15 publications met  these criteria and, in addition,
ata from three independent cohorts were obtained. Altogether
 total of 18 datasets were included in this meta-analysis. Cri-
eria for exclusion were as follows: non-neuropsychiatric brain
isorder (multiple sclerosis; Dinacci et al., 2011; Liguori et al.,
009; Ramasamy et al., 2011; Weinstock-Guttman et al., 2007;
ivadinov et al., 2007), Alzheimer’s disease (Honea et al., 2013; Lim
t al., 2014; Voineskos et al., 2011), reversible cerebral vasocon-
triction syndrome (Chen et al., 2011), alcohol-dependence (Mon
t al., 2013), premenstrual dysphoric disorder (Comasco et al.,
014), obesity (Marqués-Iturria et al., 2014)), no clearly deﬁned
atient group, overlapping datasets, and only left or right hip-
ocampal volumes reported. The authors were contacted when
ssential information was missing for the calculation of effect
izes.
.2. Data extraction
We  extracted the following variables: First author, publication
ear, number of independent samples per study. For each inde-
endent sample, we extracted sample size of genotype subgroups,
thnicity, gender, mean age, Hardy–Weinberg equilibrium (HWE;
alculated, when not reported), genotyping method, structural MRI
easurement technique, direction of effect, ﬁeld strength of MR
canner, disorder itself, duration of disorder, age of onset of dis-
rder and medication (antipsychotics, antidepressants), whether
he hippocampal volumes were normalised to intracranial volume
ICV) or not and ﬁnally, mean hippocampal volumes and standard
eviation per genotype or corresponding t-statistic, F-statistic and
-values. One single effect size per sample was included in this
eta-analysis, in order to sustain statistical independence.studies included in the meta-analysis.
2.3. Quality assessment
The Newcastle-Ottawa Scale (NOS) (Wells et al., 2014) was
adapted to assess the quality of each study as recommended by
the Higgins and Green (2011) (“Cochrane Handbook for Systematic
Reviews of Interventions”). 0 or 1 point was  awarded for each of the
eight criteria, giving a total score of high (above 80% of the maxi-
mal  sum of points), moderately high (60–79%), moderate (40–59%),
moderately low (20–39%), or low (below 19%). The mean quality
was moderately high at 76% (for more details see Supplementary
Table 1).
2.4. Meta-analytic procedure
Quantitative meta-analysis was performed using R 3.0.2 sta-
tistical software (R Core Team, 2012). The extracted data were
converted to Hedge’s g effect sizes, which provides an unbiased
standardised mean difference and – in contrast to Cohen’s d – incor-
porates a correction for small sample sizes (Lipsey and Wilson,
2000). Hedge’s g was calculated from mean hippocampal vol-
umes, standard deviations and sample sizes; where these data were
not available, the t-statistic, F-statistic or p-values together with
the corresponding sample sizes were used. Random effects model
were employed with the DerSimonian–Laird estimator, using the
metafor package 1.9.2 in R (DerSimonian and Laird, 1986; Wolfgang
Viechtbauer, 2010). The random effects model shows more ﬂexibil-
ity with respect to variable effect size in different studies and study
populations (Cooper et al., 2009), as it incorporates the between-
study variance 2. With high between-study heterogeneity, the
random effects model is the model of choice, rather than the ﬁxed-
effects model (Ioannidis et al., 2007). Cochran’s Q test was used
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nd the magnitude of heterogeneity was assessed by I2 (I2 > 50%:
igh) (Higgins and Thompson, 2002). We  investigated potential
ublication bias by funnel plot asymmetry and Egger’s regression
est (Egger et al., 1997). In the presence of a bias, the “trim-and-ﬁll”
ethod was performed (Duval and Tweedie, 2000). Power analy-
is was performed using G*Power (Faul et al., 2007). For sensitivity
nalysis, the potential inﬂuence of each individual study was  exam-
ned by excluding each study in turn (Viechtbauer and Cheung,
010). Moreover, meta-regression analyses were carried out to
ssess the impact of possible moderating factors such as publica-
ion year, age of participants, gender ratio, ethnicity, Val/Met ratio,
ample size, quality rating, magnetic ﬁeld strength, type of disorder
major depressive disorder, bipolar disorder, anxiety disorders and
chizophrenia) and applied hippocampal measuring techniques. All
ut two studies used a dominant allele approach (Agartz et al.,
006; Gruber et al., 2012). Nevertheless, these were treated equiv-
lently in this analysis. Data from healthy individuals is available
n Harrisberger et al. (2014). Finally, effect sizes were compared to
ssess whether Val/Val homozygotes or Met-carriers with a neu-
opsychiatric disorder might have a greater risk of hippocampal
oss.
. Results
.1. Description of studies
All included studies were published between 2005 and 2013.
 total of 1695 subjects from 18 independent datasets were
elected for this random effects meta-analysis (mean age ± SD:
3.13 ± 11.13 years, 56% females) (Aas et al., 2013; Agartz et al.,
006; Chepenik et al., 2009; Cole et al., 2011; Dutt et al., 2009;
rodl et al., 2007; Gonul et al., 2011; Gruber et al., 2012; Jessen
t al., 2009; Kanellopoulos et al., 2011; Koolschijn et al., 2010;
olendijk et al., 2012b; Smith et al., 2012; Szeszko et al., 2005;
akahashi et al., 2008). The meta-analysis of structural MRI  hip-
ocampal volumes comprised 661 Met-carriers and 1034 Val/Val
omozygotes. Ethnicity was reported in 14 samples, of which 11
ere of Caucasian origin, one a Japanese sample and two of mixed
thnicity. The Hardy–Weinberg equilibrium did not deviate in 17
atasets, whereas this parameter could not be calculated from
ne dataset, due to insufﬁcient data. The assessment of the BDNF
s6265 genotype frequency showed similar results for all disorders
Supplementary Fig. 1A). A comparison of the mean hippocampal
olumes in Val/Val homozygotes and Met-carriers for each disor-
er separately resulted in non-signiﬁcant volumetric alterations
etween the genotypes of each disorder (Supplementary Fig. 1B).
etails of the included studies are presented in Table 1. Quality
nalysis showed that most of the included studies were rated as
eing of high or moderately high quality (22% and 50%, respectively,
upplementary Table 1).
.2. Meta-analysis of neuropsychiatric patients
The random effects meta-analysis of all datasets (k = 18,
 = 1695) showed no evidence for a signiﬁcant association
etween hippocampal volumes and the BDNF SNP rs6265 (g = 0.11,
5%CI = [−0.02–0.25], p = 0.11, see Supplementary Fig. 2A and
able 2). The visual inspection of the funnel plot and the Egger’s
egression test (p = 0.03) revealed a potential publication bias. In
rder to account for this bias, the trim-and-ﬁll procedure sug-
ested one missing study on the left side of the funnel plot, leading
o a smaller effect size (g = 0.09, 95%CI = [−0.06–0.25], p = 0.22),
Table 2). Evidence of moderate between-study heterogeneity was
etected (I2 = 38.29%, Q(df = 17) = 27.55, p = 0.05), while a meta-
egression analyses indicated that this can probably be explained,ehavioral Reviews 55 (2015) 107–118
in part, by the year of publication (  ˇ = −0.53, F(1,16) = 6.34, p = 0.02,
Fig. 2C, Table 2). The other tested confounders, age of participants,
gender ratio, ethnicity, Val/Met ratio, sample size, quality rating,
magnetic ﬁeld strength, type of disorder (major depressive dis-
order, bipolar disorder, anxiety disorders or schizophrenia) and
applied hippocampal measuring techniques did not signiﬁcantly
inﬂuence the meta-analytic result (Table 2). Power analysis sug-
gested that 1665 Val/Val homozygote and 1065 Met-carriers (2730
patients in total) would be necessary to achieve a power of 80%
at -level of 0.05 (two-sided). Sensitivity analysis indicated that
two studies (Chepenik et al., 2009; Szeszko et al., 2005) with stan-
dardised residuals larger than ± 1.96 might be potential outliers
(Supplementary Fig. 3). Removal of these two studies might reduce
the amount of heterogeneity and increase the precision of the effect
size.
After excluding these two studies (k = 16, n = 1656), the mixed-
effect model showed an even smaller and non-signiﬁcant effect
size (g = 0.07, 95%CI = [−0.03–0.22], p = 0.16, see Fig. 2A and
Table 2), but with a non-signiﬁcant Egger’s regression test (p = 0.98)
and no signiﬁcant between-study heterogeneity (I2 = 0.75%,
Q(df = 15) = 15.11, p = 0.44). The investigation of the lateral dif-
ferences revealed the same magnitude of effect as in the latter
meta-analysis, using either left (g = 0.09, 95%CI = [−0.02–0.19],
p = 0.12, k = 14, n = 1541, see Supplementary Fig. 2B and Table 2) or
right hippocampal volumes (g = 0.08, 95%CI = [−0.05–0.20], p = 0.22,
k = 14, n = 1541, see Supplementary Fig. 2C and Table 2). Data from
two studies were not available and could not be included (Agartz
et al., 2006; Gruber et al., 2012).
3.3. Meta-analysis of patients versus healthy controls with the
same allele
Furthermore, we  investigated the difference in magnitude
between patients and healthy controls of the same genotype,
using the recessive model of the BDNF Val allele. For this anal-
ysis, one study was  excluded from further analysis due to the
lack of a healthy control sample (Aas et al., 2013) and two  stud-
ies could not be further included because of missing data (Agartz
et al., 2006; Gruber et al., 2012). The meta-analysis of Val/Val
homozygous individuals (k = 13, n = 2265) revealed that Val/Val
homozygous neuropsychiatric patients had smaller hippocam-
pal volumes than Val/Val homozygous healthy controls (g = 0.32,
95%CI = [0.11–0.54], p = 0.004, see Fig. 3A and Table 2). The meta-
analysis of Met-carriers (k = 13, n = 1255) indicated that Met-carrier
neuropsychiatric patients had smaller hippocampal volumes than
did Met-carrier healthy controls (g = 0.20, 95%CI = [0.06–0.33],
p = 0.004, see Fig. 3B and Table 2). As expected, the effect was  in
the direction of smaller hippocampal volumes for patients than for
healthy controls for both alleles. However, the effect sizes were
not signiﬁcantly different for these two comparisons (F(1,24) = 0.36,
p = 0.55)). Visual inspection of the funnel plot as well as the
Egger’s regression test (p = 0.10, p = 0.13) indicated no potential
bias. No moderator was detected as a potential source of hetero-
geneity, although the between-study heterogeneity for the Val/Val
meta-analysis was  high and signiﬁcant (p < 0.0001) (Table 2). Sep-
arate inspection of left and right hippocampal volumes for Val/Val
homozygotes and Met-carriers revealed comparable effect-sizes
to the combined meta-analysis (see Supplementary Fig. 2D–G and
Table 2).
4. DiscussionThis meta-analysis addressed the relation between hippocam-
pal volumes and the BDNF rs6265 genotype in a neuropsychiatric




















Overview of included imaging genetics studies.

























+ + 32.7 (10.9)* 54/52 Caucasian – 30 76 y Affymetrix
Human SNP 6.0
+ 1.5 < FreeSurfer: ROI
Agartz et al.
(2006)




2009 20 BD − + 40 (9) 11/9 Mixed – 8 12 y◦ TaqMan + 1.5 < Manual tracing
Cole et al.
(2011)
2011 79 MDD  − + 48.8 (8.9) 57/27 Not
stated
– 32 47 y PCR-RFLP or
TaqMan
+ 1.5 < Manual tracing
Dutt et al.
(2009)
2009 128 Psychosis 36.2 (10.4) 64/82 Caucasian – 39 89 y SNuPe
technology
− 1.5 < Manual tracing
Frodl et al.
(2007)
2007 60 MDD  − + 44.2 (11.8) 29/31 Not
stated
2 21 37 y RT-PCR + 1.5 < Manual tracing
Gonul et al.
(2011)
2011 33 MDD  − − 33.9 (9.9) 25/5 Not
stated
– 18 15 y RT-PCR + 1.5 > Manual tracing
Gruber et al.
(2012)
2012 66 BD, SCZ + + 38.2 (12.8)* 49/57 * Caucasian 1 27 38 y PCR-RFLP + 1.5 > Manual tracing
Jessen et al.
(2009)
2009 79 MDD  48.2 (12.8) 52/27 Not
stated








2010 87 SCZ + − 36.1 (12.8) 16/71 Caucasian 4 28 55 y Illumina Bead
Array






− + 37.4 (10.1)* 100/57* Caucasian 2 36 76 y◦ Single
genotyping
array




2012 58 FEP + + 20.6 (4.8) 20/38 Mixed – 20 38 y TaqMan + 1.5 > FreeSurfer: ROI
Szeszko et al.
(2005)




2008 33 SCZ + − 25.6 (4.5) 13/20 Japanese 6 15 12 y PCR-RFLP + 1.5 < Manual tracing
MPIP  2012 373 MDD  − + 47.4 (13.8) 213/160 European 18 121 234 y Illumina
100–660 K
+ 1.5 < FSL FIRST: ROI
SHIP  2012 226 MDD,
BD,
Anxiety
− + 52.1 (11.1) 159/67 European 7 70 149 y Affymetrix
Human SNP 6.0
+ 1.5 < FreeSurfer 5.1:
ROI
SHIP-TREND 2012 132 MDD  − + 49.8 (12.0) 98/34 European 4 43 85 y Illumina
Human Omni
2.5 M
+ 1.5 > FreeSurfer 5.1:
ROI
Abbreviations:  AD, antidepressants; AP, antipsychotics; BD, Bipolar disorder; FEP, ﬁrst-episode prychosis; HWE, Hardy–Weinberg equilibrium; ICV, intracranial volume; Met, methionine; MDD, major depressive disorder; MPIP,
Munich  Morphometry Sample of the Max  Planck Institute of Psychiatry; ROI, region of interest; SCZ, schizophrenia; SHIP, study of health in Pomerania; SHIP-TREND, study of health in pomerania (independent cohort); Val, valine;
VBM,  voxel-based morphometry.
* Reported of larger sample only.
? Not possible to calculate.
◦ Calculated of raw data.
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All patient data (k = 18,
n  = 1695)
0.11 0.07 −0.02 0.25 1.61 0.11 38.29 27.55 (17) 0.05
MA  without 2 studies
(k = 16, n = 1656)
0.07 0.05 −0.03 0.18 1.42 0.16 0.75 15.11 (15) 0.44
MDD  only (k = 8,
n = 903)
0.08 0.07 −0.05 0.22 1.21 0.23 0.00 5.84 (7) 0.56
L  Hippocampus (k = 14,
n  = 1541)
0.09 0.06 −0.02 0.19 1.54 0.12 3.53 13.48 (13) 0.41
R  Hippocampus (k = 14,
n = 1541)
0.08 0.06 −0.05 0.20 1.22 0.22 22.97 16.88 (13) 0.21
Patient  vs. HC Val
(k = 13, n = 2265)
0.32 0.11 0.11 0.54 2.92 0.004* 77.37 53.03 (12) <0.0001*
Patient vs. HC Val L
(k  = 13, n = 2265)
0.31 0.11 0.10 0.52 2.92 0.004* 75.31 4860 (12) <0.0001*
Patient vs. HC Val R
(k  = 13, n = 2265)
0.29 0.12 0.06 0.51 2.47 0.01* 79.60 58.82 (12) <0.0001*
Patient vs. HC Met
(k = 13, n = 1255)
0.20 0.07 0.06 0.33 2.89 0.004* 7.58 12.98 (12) 0.37
Patient  vs. HC Met L
(k = 13, n = 1255)
0.22 0.07 0.08 0.35 3.10 0.002* 11.44 13.55 (12) 0.33
Patient  vs. HC Met R
(k = 13, n = 1255)
0.18 0.08 0.02 0.34 2.22 0.03* 30.52 17.27 (12) 0.14





















All patient data (k = 18,
n  = 1695)
0.03 1 0.02* 0.51 0.39 0.53 0.28 0.85 0.51 0.45
MA  without 2 studies
(k = 16, n = 1656)
0.98 0 0.40 0.69 0.80 0.51 0.98 0.80 0.27 0.84
MDD  only (k = 8,
n = 903)
0.75 0 0.37 0.94 na 0.27 0.84 0.41 0.54 0.98
L  Hippocampus (k = 14,
n  = 1541)
0.85 1 0.26 0.74 0.71 0.79 0.83 0.39 0.15 0.87
R  Hippocampus (k = 14,
n = 1541)
0.60 1 0.79 0.47 0.72 0.45 0.74 0.80 0.22 0.97
Patient vs. HC Val
(k = 13, n = 2265)
0.10 0 0.43 na na 0.26 0.11 0.93 0.36 0.30
Patient vs. HC Val L
(k  = 13, n = 2265)
0.002 0 0.27 na na 0.49 0.02* 0.43 0.76 0.03
Patient vs. HC Val R
(k  = 13, n = 2265)
0.96 0 0.45 na na 0.48 0.50 0.83 0.56 0.56
Patient vs. HC Met
(k = 13, n = 1255)
0.13 2 0.44 na na 0.25 0.36 0.21 0.57 0.05
Patient vs. HC Met L
(k = 13, n = 1255)
0.07 2 0.20 na na 0.42 0.24 0.47 0.39 0.04*
Patient vs. HC Met R
(k = 13, n = 1255)
0.47 0 0.88 na na 0.07 0.57 0.16 0.89 0.15














Mbbreviation: MDD: major depressive disorder; Met: methionine; na: not assessed
* Signiﬁcant.
ippocampal volumes between patients and controls of the same
enotype. The ﬁrst meta-analysis did not support an association
etween hippocampal volumes and the BDNF rs6265 genotype in
europsychiatric patients, either for the left, or for the right, or for
he bilateral hippocampus. This ﬁnding is of the same magnitude as
ound in previous meta-analyses of patients (Kambeitz et al., 2012;
olendijk et al., 2012a). The present ﬁnding in patients, as well
s the negative ﬁnding in a recently published meta-analysis in
ealthy individuals (Harrisberger et al., 2014), might suggest that
tructural hippocampal differences are not primarily dependent
n the BDNF polymorphism in humans. In further meta-analyses,
e investigated the relative hippocampal loss of Val/Val homozy-
ous neuropsychiatric patients versus healthy controls and also
et-carrier patients versus healthy controls. These meta-analysesvaline.
revealed a signiﬁcant association of the left, the right and the bilat-
eral hippocampal volumes with the rs6265 polymorphism. It was
conﬁrmed that neuropsychiatric patients had smaller hippocampal
volumes than healthy controls, regardless of the genotype. This
ﬁnding corresponds with other studies in major neuropsychiatric
disorders that found smaller hippocampal volumes in patients
(e.g. review Geuze et al., 2005). In this study, however, we were
interested in whether there is a difference in magnitude between
the genotypes. We  found that the reductions in hippocampal
volume in neuropsychiatric patients relative to healthy controls
did not depend on the speciﬁc genotype, which suggests that other
factors drive the reductions in hippocampal volume in patients.
Neuropsychiatric patients appeared to have similar hippocampal
volumes, irrespective of their BDNF rs6265 genotype. Moreover,
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Fig. 2. (A) Forest plot of random effects meta-analysis investigating the association between hippocampal volumes and the BDNF SNP rs6265. Positive effect sizes indicate


















eB)  Funnel plot of potential bias where trim and ﬁll procedure revealed no missing st
eﬂecting the association between year of publication and effect size. Circle size is p
ippocampal volume loss was similar for the two  investigated
enotypes in neuropsychiatric patients relative to healthy controls.
This might suggest that the rs6265 SNP is not inherently
nvolved in the loss of hippocampal volume in neuropsychiatric
atients and that the Met  allele might not be a possible risk allele
A/Met) for depression and schizophrenia or a protective allele for
ipolar disorder. Further investigation is needed on how this poly-
orphism can affect any reduction in secreted BDNF and what
his means for cellular processing. As reported by several studies,
 promising direction for future work might be the ﬁeld of gene-
nvironment (G × E) interaction and also psychopharmacological
nterventions. For example, most previous studies investigating
nteractions between the BDNF rs6265 and stressful life events,
rauma or childhood abuse indicated smaller hippocampal volumes
n Met-carriers with adversity (Aas et al., 2013; Carballedo et al.,
013; Frodl et al., 2014; Gatt et al., 2009; Gerritsen et al., 2012; Joffe
t al., 2009; Molendijk et al., 2012b; Rabl et al., 2014). Along this line, to correct for potential publication bias. (C) Bubble plot of meta-regression analysis
tional to the inverse of the variance, and thus to the precision of each study.
the hippocampal—hypothalamus–pituitary–adrenocortical path-
way and the medial PFC-hippocampal-amygdala pathway may  be
necessary in the regulation of stress (Ninan, 2014; Rosas-Vidal
et al., 2014). Thus hippocampal volume loss and also impairment
of cognitive functions might be associated with decreased BDNF
availability in these pathways, where Val/Val and Met-carriers dif-
fer in coping with stress, thereby exacerbating symptom severity.
Unfortunately, however, we could not evaluate such aspects in
our meta-analysis, as most studies did not report environmental
factors. Furthermore, preliminary results indicate that the BDNF
level is elevated by neuropsychiatric medication and most studies
showed that the treatment response to lithium, citalopram, esci-
talopram or ﬂuoxetine (antidepressants in general) was  more efﬁ-
cient for BDNF Met-carriers (Choi et al., 2006; Dmitrzak-Weglarz
et al., 2008; El-Hage et al., 2014; Rybakowski et al., 2005; Tsai et al.,
2003; Zou et al., 2010), whereas Val/Val homozygotes responded
better to clozapine, olanzapine, risperidone and quetiapine (Grande
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Fig. 3. (A) Forest plot of random-effects meta-analyses investigating the association between hippocampal volumes and the BDNF SNP rs6265 in Val/Val homozygote patients
and  healthy controls. Positive effect sizes indicate larger hippocampi for healthy control subjects than neuropsychiatric patients. Dashed lines indicate zero line. Funnel plot of
potential bias where trim and ﬁll procedure revealed no missing studies to correct for potential publication bias. (B) Forest plot of random effects meta-analyses investigating
the  association between hippocampal volumes and the BDNF SNP rs6265 in Met-carrier patients and healthy controls. Positive effect sizes indicate larger hippocampi for
















tealthy control subjects than patients. Dashed lines indicate zero line. Funnel plot
ublication bias obtained by trim and ﬁll procedure.
t al., 2014; Hong et al., 2003; Perkovic et al., 2014; Xu et al.,
010; Zai et al., 2012). This opens up a whole new ﬁeld of person-
lised medicine/patient treatment. The opposing effects of BDNF
xpression in the hippocampus during stress and neuropsychiatric
edication should be further investigated. Another important issue
s whether and how the balance between pro-BDNF and mature
DNF is affected by the rs6265 polymorphism, bearing in mind that
ro-BDNF promotes cell apoptosis and long-term depression while
ature BDNF supports cell survival and long-term potentiation
Barde, 1989; Lee et al., 2001; Park and Poo, 2013) at hippocampal
ynapses. Some limitations need to be considered. First, the hetero-
eneity detected in the meta-analysis may  have come from other
oderators, such as medication, duration of illness or drug use,
hich were unfortunately not available for most studies. Moreover,
he p-values of the meta-analysis were not adjusted for multipletential bias where white dots indicate the missing studies to correct for potential
comparison. Second, a major limitation of this meta-analysis is that
most original studies were underpowered and this tends to reduce
the power of the meta-analysis. For this reason, the absence of an
association between the BDNF rs6265 genotype and hippocampal
volume must be conﬁrmed by meta-analyses including additional
replication studies, preferably with large datasets. Third, most of
the included studies conducted their research on individuals of
Caucasian origin where the Met/Met variant is normally very rare
(Petryshen et al., 2010) and no comparison with heterozygote indi-
viduals is possible. The only study with an Asian sample (Takahashi
et al., 2008), and thus with a larger proportion of Met/Met homozy-
gotes, did not look into this issue. Fourth, it could not be evaluated
how the known ethnic differences (Petryshen et al., 2010; Shimizu
et al., 2004) would affect the result, as most studies were conducted
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isorders in the reported risk allele might imply different outcomes
or the individual disorders. To investigate this issue, more studies
ould be needed for each of these disorders. Finally, differences in
ippocampal sub-regions between rs6265 genotypes might shed
ight on the involvement of impaired anatomical connectivity in the
rain. If a sub-region of the hippocampus is altered in volume, the
nterrelated cortical and subcortical brain regions, such as the pre-
rontal cortex or amygdala (Ninan, 2014; Rosas-Vidal et al., 2014),
hould also be included in further investigations to assess possible
mpairments in the network. The present meta-analysis does not
upport the existence of BDNF-dependent volume differences in
he hippocampus of neuropsychiatric patients. The signiﬁcant asso-
iation between hippocampal volumes and the rs6265 SNP for neu-
opsychiatric patients versus healthy controls conﬁrms previous
esults and does not support the risk hypothesis of the Met-allele.
cknowledgments
Special thanks go to Dr. Philipp Saemann, Dr. Elisabeth Binder,
r. Michael Czisch, Dr. Neeltje van Haren and Dr. Marc Molendijk
ho provided additional information and volumetric data. This
tudy was supported by the University of Basel.
ppendix A. Supplementary data
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.neubiorev.2015.
4.017
eferences
as, M.,  Haukvik, U.K., Djurovic, S., Bergmann, Ø., Athanasiu, L., Tesli, M.S., Hellvin,
T., Steen, N.E., Agartz, I., Lorentzen, S., Sundet, K., Andreassen, O.A., Melle, I.,
2013. BDNF val66met modulates the association between childhood trauma,
cognitive and brain abnormalities in psychoses. Prog. Neuro-Psychopharmacol.
Biol. Psychiatry 46, 181–188, http://dx.doi.org/10.1016/j.pnpbp.2013.07.008
gartz, I., Sedvall, G.C., Terenius, L., Kulle, B., Frigessi, A., Hall, H., Jönsson, E.G.,
2006. BDNF gene variants and brain morphology in schizophrenia. Am.  J. Med.
Genet. B: Neuropsychiatr. Genet. 141B, 513–523, http://dx.doi.org/10.1002/
ajmg.b.30338
aig, B.J., Whalley, H.C., Hall, J., McIntosh, A.M., Job, D.E., Cunningham-Owens, D.G.,
Johnstone, E.C., Lawrie, S.M., 2010. Functional magnetic resonance imaging of
BDNF val66met polymorphism in unmedicated subjects at high genetic risk of
schizophrenia performing a verbal memory task. Psychiatry Res.: Neuroimaging
183, 195–201, http://dx.doi.org/10.1016/j.pscychresns.2010.06.009
aj, G., Carlino, D., Gardossi, L., Tongiorgi, E., 2013. Toward a uniﬁed biological
hypothesis for the BDNF Val66Met-associated memory deﬁcits in humans: a
model of impaired dendritic mRNA trafﬁcking. Front Neurosci. 7, 188, http://dx.
doi.org/10.3389/fnins.2013.00188
arde, Y.-A., 1989. Trophic factors and neuronal survival. Neuron 2, 1525–1534,
http://dx.doi.org/10.1016/0896-6273(89)90040-8
ora, E., Yücel, M.,  Pantelis, C., 2010. Cognitive impairment in schizophrenia and
affective psychoses: implications for DSM-V criteria and beyond. Schizophr. Bull.
36,  36–42, http://dx.doi.org/10.1093/schbul/sbp094
ourne, C., Aydemir, Ö., Balanzá-Martínez, V., Bora, E., Brissos, S., Cavanagh, J.T.O.,
Clark, L., Cubukcuoglu, Z., Dias, V.V., Dittmann, S., Ferrier, I.N., Fleck, D.E., Fran-
gou, S., Gallagher, P., Jones, L., Kieseppä, T., Martínez-Aran, A., Melle, I., Moore,
P.B.,  Mur, M.,  Pfennig, A., Raust, A., Senturk, V., Simonsen, C., Smith, D.J., Bio, D.S.,
Soeiro-de-Souza, M.G., Stoddart, S.D.R., Sundet, K., Szöke, A., Thompson, J.M.,
Torrent, C., Zalla, T., Craddock, N., Andreassen, O.A., Leboyer, M.,  Vieta, E., Bauer,
M.,  Worhunsky, P.D., Tzagarakis, C., Rogers, R.D., Geddes, J.R., Goodwin, G.M.,
2013. Neuropsychological testing of cognitive impairment in euthymic bipolar
disorder: an individual patient data meta-analysis. Acta Psychiatr. Scand. 128,
149–162, http://dx.doi.org/10.1111/acps.12133
uchmann, A.F., Hellweg, R., Rietschel, M.,  Treutlein, J., Witt, S.H., Zimmermann, U.S.,
Schmidt, M.H., Esser, G., Banaschewski, T., Laucht, M.,  Deuschle, M.,  2013. BDNF
Val 66 Met  and 5-HTTLPR genotype moderate the impact of early psychosocial
adversity on plasma brain-derived neurotrophic factor and depressive symp-
toms: a prospective study. Eur. Neuropsychopharmacol. 23, 902–909, http://dx.
doi.org/10.1016/j.euroneuro.2012.09.003uehlmann, E., Berger, G.E., Aston, J., Gschwandtner, U., Pﬂueger, M.O., Borgwardt,
S.J., Radue, E.-W., Riecher-Rössler, A., 2010. Hippocampus abnormalities in at
risk mental states for psychosis? A cross-sectional high resolution region of
interest magnetic resonance imaging study. J. Psychiatr. Res. 44, 447–453, http://
dx.doi.org/10.1016/j.jpsychires.2009.10.008ehavioral Reviews 55 (2015) 107–118 115
Carballedo, A., Morris, D., Zill, P., Fahey, C., Reinhold, E., Meisenzahl, E., Bondy, B.,
Gill, M.,  Möller, H.-J., Frodl, T., 2013. Brain-derived neurotrophic factor Val66Met
polymorphism and early life adversity affect hippocampal volume. Am.  J. Med.
Genet. 162, 183–190, http://dx.doi.org/10.1002/ajmg.b.32130
Chen, L., Lawlor, D.A., Lewis, S.J., Yuan, W.,  Abdollahi, M.R., Timpson, N.J., Day, I.N.M.,
Ebrahim, S., Smith, G.D., Shugart, Y.Y., 2008. Genetic association study of BDNF
in  depression: Finding from two cohort studies and a meta-analysis. Am.  J. Med.
Genet. 147B, 814–821, http://dx.doi.org/10.1002/ajmg.b.30686
Chen, S.-P., Fuh, J.-L., Wang, S.-J., Tsai, S.-J., Hong, C.-J., Yang, A.C., 2011. Brain-
derived neurotrophic factor gene Val66Met polymorphism modulates reversible
cerebral vasoconstriction syndromes. PLoS ONE 6, e18024, http://dx.doi.org/10.
1371/journal.pone.0018024
Chen, Z.-Y., Jing, D., Bath, K.G., Ieraci, A., Khan, T., Siao, C.-J., Herrera, D.G., Toth,
M.,  Yang, C., McEwen, B.S., Hempstead, B.L., Lee, F.S., 2006. Genetic variant
BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 314,
140–143, http://dx.doi.org/10.1126/science.1129663
Chen, Z.-Y., Patel, P.D., Sant, G., Meng, C.-X., Teng, K.K., Hempstead, B.L., Lee, F.S.,
2004. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the
intracellular trafﬁcking and activity-dependent secretion of wild-type BDNF in
neurosecretory cells and cortical neurons. J. Neurosci. 24, 4401–4411, http://dx.
doi.org/10.1523/JNEUROSCI.0348-04.2004
Chepenik, L.G., Fredericks, C., Papademetris, X., Spencer, L., Lacadie, C., Wang,
F., Pittman, B., Duncan, J.S., Staib, L.H., Duman, R.S., Gelernter, J., Blumberg,
H.P., 2009. Effects of the brain-derived neurotrophic growth factor val66met
variation on hippocampus morphology in bipolar disorder. Neuropsychophar-
macology 34, 944–951, http://dx.doi.org/10.1038/npp.2008.107
Choi, M.-J., Kang, R.-H., Lim, S.-W., Oh, K.-S., Lee, M.-S., 2006. Brain-derived neu-
rotrophic factor gene polymorphism (Val66Met) and citalopram response in
major depressive disorder. Brain Res. 1118, 176–182, http://dx.doi.org/10.1016/
j.brainres.2006.08.012
Higgins, J.P.T., Green, S. (Eds.), 2011. Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration,
Available from www.cochrane-handbook.org (accessed 06.07.14).
Cole, J., Weinberger, D.R., Mattay, V.S., Cheng, X., Toga, A.W., Thompson, P.M., Powell-
Smith, G., Cohen-Woods, S., Simmons, A., McGufﬁn, P., Fu, C.H.Y., 2011. No effect
of  5HTTLPR or BDNF Val66Met polymorphism on hippocampal morphology in
major depression. Genes Brain Behav. 10, 756–764, http://dx.doi.org/10.1111/j.
1601-183X.2011.00714.x
Comasco, E., Hahn, A., Ganger, S., Gingnell, M.,  Bannbers, E., Oreland, L., Wik-
ström, J., Epperson, C.N., Lanzenberger, R., Sundström-Poromaa, I., 2014.
Emotional fronto-cingulate cortex activation and brain derived neurotrophic
factor polymorphism in premenstrual dysphoric disorder. Hum. Brain Mapp.
35, 4450–4458, http://dx.doi.org/10.1002/hbm.22486
Cooper, H., Hedges, L.V., Valentine, J.C., 2009. The Handbook of Research Synthesis
and  Meta-Analysis, second ed. Russell Sage Foundation, New York, NY, USA.
Cunha, A.B.M., Frey, B.N., Andreazza, A.C., Goi, J.D., Rosa, A.R., Gonc¸ alves, C.A., Santin,
A.,  Kapczinski, F., 2006. Serum brain-derived neurotrophic factor is decreased
in  bipolar disorder during depressive and manic episodes. Neurosci. Lett. 398,
215–219, http://dx.doi.org/10.1016/j.neulet.2005.12.085
Cunha, C., Brambilla, R., Thomas, K.L., 2010. A simple role for BDNF in learning
and memory? Front. Mol. Neurosci. 3, 1, http://dx.doi.org/10.3389/neuro.02.
001.2010
DerSimonian, R., Laird, N., 1986. Meta-analysis in clinical trials. Control Clin Trials
7,  177–188.
Dinacci, D., Tessitore, A., Russo, A., De Bonis, M.L., Lavorgna, L., Picconi, O.,  Sacco, R.,
Bonavita, S., Gallo, A., Servillo, G., Marcuccio, L., Comerci, M.,  Galletti, P., Alfano, B.,
Tedeschi, G., 2011. BDNF Val66Met polymorphism and brain volumes in multiple
sclerosis. Neurol. Sci. 32, 117–123, http://dx.doi.org/10.1007/s10072-010-0433-
z
Dmitrzak-Weglarz, M.,  Rybakowski, J.K., Suwalska, A., Skibinska, M.,  Leszczynska-
Rodziewicz, A., Szczepankiewicz, A., Hauser, J., 2008. Association studies of
the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium
response in bipolar patients. Pharmacogenomics 9, 1595–1603, http://dx.doi.
org/10.2217/14622416.9.11.1595
Dutt, A., McDonald, C., Dempster, E., Prata, D., Shaikh, M.,  Williams, I., Schulze, K.,
Marshall, N., Walshe, M.,  Allin, M., Collier, D., Murray, R., Bramon, E., 2009. The
effect of COMT, BDNF 5-HTT, NRG1 and DTNBP1 genes on hippocampal and
lateral ventricular volume in psychosis. Psychol. Med. 39, 1783–1797, http://dx.
doi.org/10.1017/S0033291709990316
Duval, S., Tweedie, R., 2000. Trim and ﬁll: a simple funnel-plot-based method of test-
ing and adjusting for publication bias in meta-analysis. Biometrics 56, 455–463.
Egan, M.F., Kojima, M.,  Callicott, J.H., Goldberg, T.E., Kolachana, B.S., Bertolino, A.,
Zaitsev, E., Gold, B., Goldman, D., Dean, M.,  Lu, B., Weinberger, D.R., 2003. The
BDNF val66met polymorphism affects activity-dependent secretion of BDNF and
human memory and hippocampal function. Cell 112, 257–269.
Egger, M.,  Davey Smith, G., Schneider, M.,  Minder, C., 1997. Bias in meta-analysis
detected by a simple, graphical test. BMJ  315, 629–634.
El-Hage, W.,  Vourc’h, P., Gaillard, P., Léger, J., Belzung, C., Ibarguen-Vargas, Y., Andres,
C.R., Camus, V., 2014. The BDNF Val66Met polymorphism is associated with
escitalopram response in depressed patients. Psychopharmacology, 1–7, http://
dx.doi.org/10.1007/s00213-014-3694-zFaul, F., Erdfelder, E., Lang, A.-G., Buchner, A., 2007. G*Power 3: a ﬂexible statisti-
cal power analysis program for the social, behavioral, and biomedical sciences.
Behav. Res. Methods 39, 175–191.
Fernandes, B.S., Berk, M.,  Turck, C.W., Steiner, J., Gonc¸ alves, C.-A., 2014. Decreased




















H16 F. Harrisberger et al. / Neuroscience an
activity in major psychiatric disorders: a comparative meta-analysis. Mol. Psy-
chiatry 19, 750–751, http://dx.doi.org/10.1038/mp.2013.172
ernandes, B.S., Gama, C.S., Ceresér, K.M., Yatham, L.N., Fries, G.R., Colpo, G., de
Lucena, D., Kunz, M.,  Gomes, F.A., Kapczinski, F., 2011. Brain-derived neu-
rotrophic factor as a state-marker of mood episodes in bipolar disorders: a
systematic review and meta-regression analysis. J. Psychiatr. Res. 45, 995–1004,
http://dx.doi.org/10.1016/j.jpsychires.2011.03.002
rodl, T., Schüle, C., Schmitt, G., Born, C., Baghai, T., Zill, P., Bottlender, R., Rupprecht,
R.,  Bondy, B., Reiser, M.,  Möller, H.-J., Meisenzahl, E.M., 2007. Association of
the brain-derived neurotrophic factor Val66Met polymorphism with reduced
hippocampal volumes in major depression. Arch. Gen. Psychiatry 64, 410–416,
http://dx.doi.org/10.1001/archpsyc.64.4.410
rodl, T., Skokauskas, N., Frey, E.-M., Morris, D., Gill, M.,  Carballedo, A., 2014.
BDNFVal66Met genotype interacts with childhood adversity and inﬂuences the
formation of hippocampal subﬁelds. Hum. Brain Mapp. 35, 5776–5783, http://
dx.doi.org/10.1002/hbm.22584
rustaci, A., Pozzi, G., Gianfagna, F., Manzoli, L., Boccia, S., 2008. Meta-analysis of
the  brain-derived neurotrophic factor gene &lt;i&gt;(BDNF)&lt;/i&gt; Val66Met
polymorphism in anxiety disorders and anxiety-related personality traits. Neu-
ropsychobiology 58, 163–170, http://dx.doi.org/10.1159/000182892
usar-Poli, P., Deste, G., Smieskova, R., Barlati, S., Yung, A.R., Howes, O., Stieglitz, R.-
D.,  Vita, A., McGuire, P., Borgwardt, S., 2012. Cognitive functioning in prodromal
psychosis: a meta-analysis. Arch. Gen. Psychiatry 69, 562–571, http://dx.doi.org/
10.1001/archgenpsychiatry.2011.1592
usar-Poli, P., Perez, J., Broome, M.,  Borgwardt, S., Placentino, A., Caverzasi, E., Cortesi,
M.,  Veggiotti, P., Politi, P., Barale, F., McGuire, P., 2007. Neurofunctional correlates
of  vulnerability to psychosis: a systematic review and meta-analysis. Neurosci.
Biobehav. Rev. 31, 465–484, http://dx.doi.org/10.1016/j.neubiorev.2006.11.006
att, J.M., Nemeroff, C.B., Dobson-Stone, C., Paul, R.H., Bryant, R.A., Schoﬁeld,
P.R., Gordon, E., Kemp, A.H., Williams, L.M., 2009. Interactions between BDNF
Val66Met polymorphism and early life stress predict brain and arousal path-
ways to syndromal depression and anxiety. Mol. Psychiatry 14, 681–695, http://
dx.doi.org/10.1038/mp.2008.143
erritsen, L., Tendolkar, I., Franke, B., Vasquez, A.A., Kooijman, S., Buitelaar, J., Fer-
nández, G., Rijpkema, M.,  2012. BDNF Val66Met genotype modulates the effect
of childhood adversity on subgenual anterior cingulate cortex volume in healthy
subjects. Mol. Psychiatry 17, 597–603, http://dx.doi.org/10.1038/mp.2011.51
euze, E., Vermetten, E., Bremner, J.D., 2005. MR-based in vivo hippocampal volu-
metrics: 2. Findings in neuropsychiatric disorders. Mol. Psychiatry 10, 160–184,
http://dx.doi.org/10.1038/sj.mp.4001579
onul, A.S., Kitis, O., Eker, M.C., Eker, O.D., Ozan, E., Coburn, K., 2011. Association
of  the brain-derived neurotrophic factor Val66Met polymorphism with hip-
pocampus volumes in drug-free depressed patients. World J. Biol. Psychiatry
12, 110–118, http://dx.doi.org/10.3109/15622975.2010.507786
onzález-Castro, T.B., Nicolini, H., Lanzagorta, N., López-Narváez, L., Genis, A., Pool
García, S., Tovilla-Zárate, C.A., 2014. The role of brain-derived neurotrophic fac-
tor  (BDNF) Val66Met genetic polymorphism in bipolar disorder: a case-control
study, comorbidities, and meta-analysis of 16,786 subjects. Bipolar Disord.,
n/a–n/a, http://dx.doi.org/10.1111/bdi.12227
rande, I., Magalhães, P.V.S., Chendo, I., Stertz, L., Fries, G.R., Cereser, K.M., Cunha,
Â.B.M., Gói, P., Kunz, M.,  Udina, M.,  Martín-Santos, R., Frey, B.N., Vieta, E.,
Kapczinski, F., 2014. Val66Met polymorphism and serum brain-derived neu-
rotrophic factor in bipolar disorder: an open-label trial. Acta Psychiatr. Scand.
129, 393–400, http://dx.doi.org/10.1111/acps.12192
ratacòs, M., González, J.R., Mercader, J.M., de Cid, R., Urretavizcaya, M., Estivill, X.,
2007. Brain-derived neurotrophic factor Val66Met and psychiatric disorders:
meta-analysis of case-control studies conﬁrm association to substance-related
disorders, eating disorders, and schizophrenia. Biol. Psychiatry 61, 911–922,
http://dx.doi.org/10.1016/j.biopsych.2006.08.025
reen, M.J., Matheson, S.L., Shepherd, A., Weickert, C.S., Carr, V.J., 2011. Brain-derived
neurotrophic factor levels in schizophrenia: a systematic review with meta-
analysis. Mol. Psychiatry 16, 960–972, http://dx.doi.org/10.1038/mp.2010.88
ruber, O., Hasan, A., Scherk, H., Wobrock, T., Schneider-Axmann, T., Ekawardhani,
S.,  Schmitt, A., Backens, M.,  Reith, W.,  Meyer, J., Falkai, P., 2012. Association of
the brain-derived neurotrophic factor val66met polymorphism with magnetic
resonance spectroscopic markers in the human hippocampus: in vivo evidence
for effects on the glutamate system. Eur. Arch. Psychiatry Clin. Neurosci. 262,
23–31, http://dx.doi.org/10.1007/s00406-011-0214-6
arrisberger, F., Spalek, K., Smieskova, R., Schmidt, A., Coynel, D., Milnik, A., Fasten-
rath, M.,  Freytag, V., Gschwind, L., Walter, A., Vogel, T., Bendfeldt, K., de Quervain,
D.J.-F., Papassotiropoulos, A., Borgwardt, S., 2014. The association of the BDNF
Val66Met polymorphism and the hippocampal volumes in healthy humans: a
joint  meta-analysis of published and new data. Neurosci. Biobehav. Rev. 42,
267–278, http://dx.doi.org/10.1016/j.neubiorev.2014.03.011
iggins, J.P.T., Thompson, S.G., 2002. Quantifying heterogeneity in a meta-analysis.
Stat. Med. 21, 1539–1558, http://dx.doi.org/10.1002/sim.1186
o, B.-C., Milev, P., O’Leary, D.S., Librant, A., Andreasen, N.C., Wassink, T.H., 2006.
Cognitive and magnetic resonance imaging brain morphometric correlates of
brain-derived neurotrophic factor Val66Met gene polymorphism in patients
with schizophrenia and healthy volunteers. Arch. Gen. Psychiatry 63, 731–740,
http://dx.doi.org/10.1001/archpsyc.63.7.731o, Beng-Choon, Andreasen, Nancy, Dawson, Jeffrey, Wassink, Thomas, 2007.
Association between brain-derived neurotrophic factor Val66Met gene
polymorphism and progressive brain volume changes in schizophrenia. Am.  J.
Psychiatry 164, 1890–1899, http://dx.doi.org/10.1176/appi.ajp.2007.05111903ehavioral Reviews 55 (2015) 107–118
Honea, R.A., Cruchaga, C., Perea, R.D., Saykin, A.J., Burns, J.M., Weinberger, D.R., Goate,
A.M., Alzheimer’s Disease Neuroimaging Initiative (ADNI), 2013. Characterizing
the  role of brain derived neurotrophic factor genetic variation in Alzheimer’s dis-
ease  neurodegeneration. PLoS ONE 8, e76001, http://dx.doi.org/10.1371/journal.
pone.0076001
Hong, C.-J., Yu, Y.W.-Y., Lin, C.-H., Tsai, S.-J., 2003. An association study of a brain-
derived neurotrophic factor Val66Met polymorphism and clozapine response of
schizophrenic patients. Neurosci. Lett. 349, 206–208, http://dx.doi.org/10.1016/
S0304-3940(03)00828-0
Ioannidis, J.P.A., Patsopoulos, N.A., Evangelou, E., 2007. Heterogeneity in meta-
analyses of genome-wide association investigations. PLoS ONE 2, e841, http://
dx.doi.org/10.1371/journal.pone.0000841
Jessen, F., Schuhmacher, A., von Widdern, O., Guttenthaler, V., Hofels, S., Suliman,
H., Scheef, L., Block, W.,  Urbach, H., Maier, W.,  Zobel, A., 2009. No association
of  the Val66Met polymorphism of the brain-derived neurotrophic factor with
hippocampal volume in major depression. Psychiatr. Genet. 19, 99–101, http://
dx.doi.org/10.1097/YPG.0b013e32832080ce
Joffe, R.T., Gatt, J.M., Kemp, A.H., Grieve, S., Dobson-Stone, C., Kuan, S.A., Schoﬁeld,
P.R., Gordon, E., Williams, L.M., 2009. Brain derived neurotrophic factor
Val66Met polymorphism, the ﬁve factor model of personality and hippocampal
volume: implications for depressive illness. Hum. Brain Mapp. 30, 1246–1256,
http://dx.doi.org/10.1002/hbm.20592
Kambeitz, J.P., Bhattacharyya, S., Kambeitz-Ilankovic, L.M., Valli, I., Collier, D.A.,
McGuire, P., 2012. Effect of BDNF val(66)met polymorphism on declarative
memory and its neural substrate: a meta-analysis. Neurosci. Biobehav. Rev. 36,
2165–2177, http://dx.doi.org/10.1016/j.neubiorev.2012.07.002
Kanazawa, T., Glatt, S.J., Kia-Keating, B., Yoneda, H., Tsuang, M.T., 2007. Meta-analysis
reveals no association of the Val66Met polymorphism of brain-derived neu-
rotrophic factor with either schizophrenia or bipolar disorder. Psychiatr. Genet.
17  (June), 165–170, http://dx.doi.org/10.1097/YPG.0b013e32801da2e2
Kandel, E.R., 2001. The molecular biology of memory storage: a dialogue between
genes and synapses. Science 294, 1030–1038, http://dx.doi.org/10.1126/science.
1067020
Kanellopoulos, D., Gunning, F.M., Morimoto, S.S., Hoptman, M.J., Murphy, C.F., Kelly,
R.E., Glatt, C., Lim, K.O., Alexopoulos, G.S., 2011. Hippocampal volumes and the
BDNF val66met polymorphism in geriatric major depression. Am.  J. Geriatr.
Psychiatry 19, 13–22.
Karege, F., Perret, G., Bondolﬁ, G., Schwald, M.,  Bertschy, G., Aubry, J.-M.,
2002. Decreased serum brain-derived neurotrophic factor levels in major
depressed patients. Psychiatry Res. 109, 143–148, http://dx.doi.org/10.1016/
S0165-1781(02)00005-7
Kempton, M.J., Salvador, Z., Munafò, M.R., et al., 2011. Structural neuroimag-
ing studies in major depressive disorder: meta-analysis and comparison with
bipolar disorder. Arch. Gen. Psychiatry 68, 675–690, http://dx.doi.org/10.1001/
archgenpsychiatry.2011.60
Koolschijn, P.C.M.P., van Haren, N.E.M., Bakker, S.C., Hoogendoorn, M.L.C., Hulshoff
Pol, H.E., Kahn, R.S., 2010. Effects of brain-derived neurotrophic factor Val66Met
polymorphism on hippocampal volume change in schizophrenia. Hippocampus
20, 1010–1017, http://dx.doi.org/10.1002/hipo.20699
Lang, U.E., Borgwardt, S., 2013. Molecular mechanisms of depression: perspectives
on new treatment strategies. Cell. Physiol. Biochem. 31, 761–777, http://dx.doi.
org/10.1159/000350094
Lau, J.Y.F., Goldman, D., Buzas, B., Hodgkinson, C., Leibenluft, E., Nelson, E., Sankin,
L.,  Pine, D.S., Ernst, M.,  2010. BDNF gene polymorphism (Val66Met) predicts
amygdala and anterior hippocampus responses to emotional faces in anxious
and  depressed adolescents. NeuroImage: Imaging Genet. 53, 952–961, http://
dx.doi.org/10.1016/j.neuroimage.2009.11.026
Lee, R., Kermani, P., Teng, K.K., Hempstead, B.L., 2001. Regulation of cell survival by
secreted proneurotrophins. Science 294, 1945–1948, http://dx.doi.org/10.1126/
science.1065057
Liguori, M.,  Fera, F., Patitucci, A., Manna, I., Condino, F., Valentino, P., Telarico,
P.,  Cerasa, A., Gioia, M.C., di Palma, G., Quattrone, A., 2009. A longitudinal
observation of brain-derived neurotrophic factor mRNA levels in patients with
relapsing-remitting multiple sclerosis. Brain Res. 1256, 123–128, http://dx.doi.
org/10.1016/j.brainres.2008.11.047
Lim, Y.Y., Villemagne, V.L., Laws, S.M., Ames, D., Pietrzak, R.H., Ellis, K.A., Har-
rington, K., Bourgeat, P., Bush, A.I., Martins, R.N., Masters, C.L., Rowe, C.C.,
Maruff, P., AIBL Research Group, 2014. Effect of BDNF Val66Met on memory
decline and hippocampal atrophy in prodromal Alzheimer’s disease: a pre-
liminary study. PLoS ONE 9, e86498, http://dx.doi.org/10.1371/journal.pone.
0086498
Lin, P.-Y., 2009. State-dependent decrease in levels of brain-derived neurotrophic
factor in bipolar disorder: a meta-analytic study. Neurosci. Lett. 466, 139–143,
http://dx.doi.org/10.1016/j.neulet.2009.09.044
Lipsey, M.W.,  Wilson, D.B., 2000. Practical Meta-Analysis. SAGE.
Lohoff, F.w., Sander, T., Ferraro, T., Dahl, n.J., Gallinat, p.J., Berrettini, W.h., 2005.
Conﬁrmation of association between the Val66Met polymorphism in the brain-
derived neurotrophic factor (BDNF) gene and bipolar I disorder. Am.  J. Med.
Genet. 139B, 51–53, http://dx.doi.org/10.1002/ajmg.b.30215
Marqués-Iturria, I., Garolera, M.,  Pueyo, R., Segura, B., Hernan, I., García-García,
I.,  Sánchez-Garre, C., Vernet-Vernet, M.,  Sender-Palacios, M.J., Narberhaus, A.,
Ariza, M., Junqué, C., Jurado, M.Á., 2014. The interaction effect between BDNF
val66met polymorphism and obesity on executive functions and frontal struc-























RF. Harrisberger et al. / Neuroscience an
cDonald, R.J., Hong, N.S., 2013. How does a speciﬁc learning and memory system
in  the mammalian brain gain control of behavior? Hippocampus 23, 1084–1102,
http://dx.doi.org/10.1002/hipo.22177
oher, D., Liberati, A., Tetzlaff, J., Altman, D.G., 2010. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. Int. J. Surg. 8,
336–341, http://dx.doi.org/10.1016/j.ijsu.2010.02.007
olendijk, M.L., Bus, B.A.A., Spinhoven, P., Kaimatzoglou, A., Oude Voshaar, R.C.,
Penninx, B.W.J.H., van IJzendoorn, M.H., Elzinga, B.M., 2012a. A systematic
review and meta-analysis on the association between BDNF val(66)met and hip-
pocampal volume—a genuine effect or a winners curse? Am.  J. Med. Genet. B:
Neuropsychiatr. Genet. 159B, 731–740, http://dx.doi.org/10.1002/ajmg.b.32078
olendijk, M.L., Spinhoven, P., Polak, M.,  Bus, B.a.A., Penninx, B.W.J.H., Elzinga,
B.M., 2014. Serum BDNF concentrations as peripheral manifestations of depres-
sion: evidence from a systematic review and meta-analyses on 179 associations
(N  = 9484). Mol. Psychiatry 19, 791–800, http://dx.doi.org/10.1038/mp.2013.
105
olendijk, M.L., van Tol, M.-J., Penninx, B.W.J.H., van der Wee, N.J.A., Aleman, A.,
Veltman, D.J., Spinhoven, P., Elzinga, B.M., 2012b. BDNF val66met affects hip-
pocampal volume and emotion-related hippocampal memory activity. Transl.
Psychiatry 2, e74, http://dx.doi.org/10.1038/tp.2011.72
on, A., Durazzo, T.C., Gazdzinski, S., Hutchison, K.E., Pennington, D., Meyerhoff,
D.J.,  2013. Brain-derived neurotrophic factor genotype is associated with brain
gray and white matter tissue volumes recovery in abstinent alcohol-dependent
individuals. Genes Brain Behav. 12, 98–107, http://dx.doi.org/10.1111/j.1601-
183X.2012.00854.x
iitsu, T., Ishima, T., Yoshida, T., Hashimoto, T., Matsuzawa, D., Shirayama, Y.,
Nakazato, M.,  Shimizu, E., Hashimoto, K., Iyo, M.,  2014. A positive correlation
between serum levels of mature brain-derived neurotrophic factor and nega-
tive  symptoms in schizophrenia. Psychiatry Res. 215, 268–273, http://dx.doi.
org/10.1016/j.psychres.2013.12.009
inan, I., 2014. Synaptic regulation of affective behaviors; role of BDNF. Neuro-
pharmacology 76 (Part C), 684–695, http://dx.doi.org/10.1016/j.neuropharm.
2013.04.011 (BDNF Regulation of Synaptic Structure, Function, and Plasticity).
inan, I., Bath, K.G., Dagar, K., Perez-Castro, R., Plummer, M.R., Lee, F.S., Chao, M.V.,
2010. The BDNF Val66Met polymorphism impairs NMDA receptor-dependent
synaptic plasticity in the hippocampus. J. Neurosci. 30, 8866–8870, http://dx.
doi.org/10.1523/JNEUROSCI.1405-10.2010
umata, S., Ueno, S., Iga, J., Yamauchi, K., Hongwei, S., Ohta, K., Kinouchi, S., Shibuya-
Tayoshi, S., Tayoshi, S., Aono, M.,  Kameoka, N., Sumitani, S., Tomotake, M.,
Kaneda, Y., Taniguchi, T., Ishimoto, Y., Ohmori, T., 2006. Brain-derived neu-
rotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated
with age at onset and symptoms. Neurosci. Lett. 401, 1–5, http://dx.doi.org/10.
1016/j.neulet.2006.02.054
an, W.,  Banks, W.A., Fasold, M.B., Bluth, J., Kastin, A.J., 1998. Transport of brain-
derived neurotrophic factor across the blood-brain barrier. Neuropharmacology
37, 1553–1561.
ark, H., Poo, M.,  2013. Neurotrophin regulation of neural circuit development and
function. Nat. Rev. Neurosci. 14, 7–23, http://dx.doi.org/10.1038/nrn3379
erkovic, M.N., Erjavec, G.N., Zivkovic, M., Sagud, M.,  Uzun, S., Mihaljevic-Peles, A.,
Kozumplik, O., Muck-Seler, D., Pivac, N., 2014. Association between the brain-
derived neurotrophic factor Val66Met polymorphism and therapeutic response
to  olanzapine in schizophrenia patients. Psychopharmacology 231, 3757–3764,
http://dx.doi.org/10.1007/s00213-014-3515-4
etryshen, T.L., Sabeti, P.C., Aldinger, K.A., Fry, B., Fan, J.B., Schaffner, S.F., Waggoner,
S.G., Tahl, A.R., Sklar, P., 2010. Population genetic study of the brain-derived
neurotrophic factor (BDNF) gene. Mol. Psychiatry 15, 810–815, http://dx.doi.
org/10.1038/mp.2009.24
illai, A., Kale, A., Joshi, S., Naphade, N., Raju, M.S.V.K., Nasrallah, H., Mahadik,
S.P., 2010. Decreased BDNF levels in CSF of drug-naive ﬁrst-episode psychotic
subjects: correlation with plasma BDNF and psychopathology. Int. J. Neuropsy-
chopharmacol. 13, 535–539, http://dx.doi.org/10.1017/S1461145709991015
reston, A.R., Eichenbaum, H., 2013. Interplay of hippocampus and prefrontal cortex
in  memory. Curr. Biol. 23, R764–R773, http://dx.doi.org/10.1016/j.cub.2013.05.
041
abl, U., Meyer, B.M., Diers, K., Bartova, L., Berger, A., Mandorfer, D., Popovic, A.,
Scharinger, C., Huemer, J., Kalcher, K., Pail, G., Haslacher, H., Perkmann, T.,
Windischberger, C., Brocke, B., Sitte, H.H., Pollak, D.D., Dreher, J.-C., Kasper, S.,
Praschak-Rieder, N., Moser, E., Esterbauer, H., Pezawas, L., 2014. Additive gene-
environment effects on hippocampal structure in healthy humans. J. Neurosci.
34,  9917–9926, http://dx.doi.org/10.1523/JNEUROSCI.3113-13.2014
amasamy, D.P., Ramanathan, M.,  Cox, J.L., Antulov, R., Weinstock-Guttman, B.,
Bergsland, N., Benedict, R.H.B., Dwyer, M.G., Minagar, A., Zivadinov, R., 2011.
Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter vol-
umes in patients with multiple sclerosis: a voxel-based morphometry study.
Pathophysiology 18, 53–60, http://dx.doi.org/10.1016/j.pathophys.2010.04.006
 Core Team, 2012. R: A Language and Environment for Statistical Computing. R Core
Team.
icken, R., Adli, M.,  Lange, C., Krusche, E., Stamm,  T.J., Gaus, S., Koehler, S., Nase, S.,
Bschor, T., Richter, C., Steinacher, B., Heinz, A., Rapp, M.A., Borgwardt, S., Hellweg,
R.,  Lang, U.E., 2013. Brain-derived neurotrophic factor serum concentrations in
acute depressive patients increase during lithium augmentation of antidepres-
sants. J. Clin. Psychopharmacol. 33 (December), 806–809, http://dx.doi.org/10.
1097/JCP.0b013e3182a412b8
osas-Vidal, L.E., Do-Monte, F.H., Sotres-Bayon, F., Quirk, G.J., 2014. Hippocampal-
prefrontal BDNF and memory for fear extinction. Neuropsychopharmacology
39, 2161–2169, http://dx.doi.org/10.1038/npp.2014.64ehavioral Reviews 55 (2015) 107–118 117
Rybakowski, J.K., Suwalska, A., Skibinska, M.,  Szczepankiewicz, A., Leszczynska-
Rodziewicz, A., Permoda, A., Czerski, P.M., Hauser, J., 2005. Prophylactic lithium
response and polymorphism of the brain-derived neurotrophic factor gene.
Pharmacopsychiatry 38, 166–170, http://dx.doi.org/10.1055/s-2005-871239
Schaefer, J., Giangrande, E., Weinberger, D.R., Dickinson, D., 2013. The global cog-
nitive impairment in schizophrenia: consistent over decades and around the
world. Schizophr. Res. 150, 42–50, http://dx.doi.org/10.1016/j.schres.2013.07.
009
Shepherd, A.M., Laurens, K.R., Matheson, S.L., Carr, V.J., Green, M.J., 2012. System-
atic  meta-review and quality assessment of the structural brain alterations in
schizophrenia. Neurosci. Biobehav. Rev. 36, 1342–1356, http://dx.doi.org/10.
1016/j.neubiorev.2011.12.015
Shimizu, E., Hashimoto, K., Iyo, M.,  2004. Ethnic difference of the BDNF 196G/A
(val66met) polymorphism frequencies: the possibility to explain ethnic men-
tal  traits. Am.  J. Med. Genet. 126B, 122–123, http://dx.doi.org/10.1002/ajmg.b.
20118
Shimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C.,
Nakazato, M.,  Watanabe, H., Shinoda, N., Okada, S., Iyo, M.,  2003. Alterations of
serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients
with or without antidepressants. Biol. Psychiatry 54, 70–75, http://dx.doi.org/
10.1016/S0006-3223(03)00181-1
Sklar, P., Gabriel, S.B., McInnis, M.G., Bennett, P., Lim, Y.-M., Tsan, G., Schaffner,
S.,  Kirov, G., Jones, I., Owen, M.,  Craddock, N., DePaulo, J.R., Lander, E.S., 2002.
Family-based association study of 76 candidate genes in bipolar disorder: BDNF
is a potential risk locus Brain-derived neutrophic factor. Mol. Psychiatry 7,
579–593, http://dx.doi.org/10.1038/sj.mp.4001058
Smith, G.N., Thornton, A.E., Lang, D.J., Macewan, G.W., Ehmann, T.S., Kopala, L.C.,
Tee, K., Shiau, G., Voineskos, A.N., Kennedy, J.L., Honer, W.G., 2012. Hippocampal
volume and the brain-derived neurotrophic factor Val66Met polymorphism in
ﬁrst  episode psychosis. Schizophr. Res. 134, 253–259, http://dx.doi.org/10.1016/
j.schres.2011.11.022
Snyder, H.R., 2013. Major depressive disorder is associated with broad impairments
on neuropsychological measures of executive function: a meta-analysis and
review. Psychol. Bull. 139, 81–132, http://dx.doi.org/10.1037/a0028727
Stein, J.L., Medland, S.E., Vasquez, A.A., Hibar, D.P., Senstad, R.E., Winkler, A.M., Toro,
R.,  Appel, K., Bartecek, R., Bergmann, Ø., Bernard, M.,  Brown, A.A., Cannon, D.M.,
Chakravarty, M.M.,  Christoforou, A., Domin, M.,  Grimm, O., Hollinshead, M.,
Holmes, A.J., Homuth, G., Hottenga, J.-J., Langan, C., Lopez, L.M., Hansell, N.K.,
Hwang, K.S., Kim, S., Laje, G., Lee, P.H., Liu, X., Loth, E., Lourdusamy, A., Mattings-
dal,  M.,  Mohnke, S., Maniega, S.M., Nho, K., Nugent, A.C., O’Brien, C., Papmeyer, M.,
Pütz, B., Ramasamy, A., Rasmussen, J., Rijpkema, M.,  Risacher, S.L., Roddey, J.C.,
Rose, E.J., Ryten, M.,  Shen, L., Sprooten, E., Strengman, E., Teumer, A., Trabzuni, D.,
Turner, J., van Eijk, K., van Erp, T.G.M., van Tol, M.-J., Wittfeld, K., Wolf, C., Woud-
stra, S., Aleman, A., Alhusaini, S., Almasy, L., Binder, E.B., Brohawn, D.G., Cantor,
R.M., Carless, M.A., Corvin, A., Czisch, M., Curran, J.E., Davies, G., de Almeida,
M.A.A., Delanty, N., Depondt, C., Duggirala, R., Dyer, T.D., Erk, S., Fagerness, J.,
Fox, P.T., Freimer, N.B., Gill, M.,  Göring, H.H.H., Hagler, D.J., Hoehn, D., Hols-
boer, F., Hoogman, M.,  Hosten, N., Jahanshad, N., Johnson, M.P., Kasperaviciute
Jr.,  D., Kochunov, J.W.K., Lancaster, P., Lawrie, J.L., Liewald, S.M., Mandl, D.C.,
Matarin, R., Mattheisen, M.,  Meisenzahl, M., Melle, E., Moses, I., Mühleisen, E.K.,
Nauck, T.W., Nöthen, M.,  Olvera, M.M.,  Pandolfo, R.L., Pike, M.,  Puls, G.B., Rein-
vang, R., Rentería, I., Rietschel, M.E., Roffman, M.,  Royle, J.L., Rujescu, N.A., Savitz,
D.,  Schnack, J., Schnell, H.G., Seiferth, K., Smith, N., Steen, C., Valdés Hernández,
V.M., Van den Heuvel, M.C., van der Wee, M.,  Van Haren, N.J., Veltman, N.E.M.,
Völzke, J.A., Walker, H., Westlye, R., Whelan, L.T., Agartz, C.D., Boomsma, I., Caval-
leri, D.I., Dale, G.L., Djurovic, A.M., Drevets, S., Hagoort, W.C., Hall, P., Heinz Jr., A.,
Foroud, C.R.J., Le Hellard, T.M., Macciardi, S., Montgomery, F., Poline, G.W., Por-
teous, J.B., Sisodiya, D.J., Starr, S.M., Sussmann, J.M., Toga, J.A.W., Veltman, D.J.,
Walter, H., Bis, J.C., Ikram, M.A., Smith, A.V., Gudnason, V., Tzourio, C., Vernooij,
M.W.,  Launer, L.J., DeCarli, C., Seshadri, S., EPIGEN Consortium, IMAGEN Con-
sortium, Saguenay Youth Study Group, Cohorts for Heart and Aging Research in
Genomic Epidemiology Consortium (CHARGE), Alzheimer’s Disease Neuroimag-
ing Initiative, 2012. Identiﬁcation of common variants associated with human
hippocampal and intracranial volumes. Nat. Genet. 44, 552–561, http://dx.doi.
org/10.1038/ng.2250
Szeszko, P.R., Lipsky, R., Mentschel, C., Robinson, D., Gunduz-Bruce, H., Sevy, S.,
Ashtari, M.,  Napolitano, B., Bilder, R.M., Kane, J.M., Goldman, D., Malhotra, A.K.,
2005. Brain-derived neurotrophic factor val66met polymorphism and volume
of  the hippocampal formation. Mol. Psychiatry 10, 631–636, http://dx.doi.org/
10.1038/sj.mp.4001656
Takahashi, T., Suzuki, M.,  Tsunoda, M.,  Kawamura, Y., Takahashi, N., Tsuneki, H.,
Kawasaki, Y., Zhou, S.-Y., Kobayashi, S., Sasaoka, T., Seto, H., Kurachi, M.,  Ozaki,
N.,  2008. Association between the brain-derived neurotrophic factor Val66Met
polymorphism and brain morphology in a Japanese sample of schizophrenia
and healthy comparisons. Neurosci. Lett. 435, 34–39, http://dx.doi.org/10.1016/
j.neulet.2008.02.004
Tsai, S.-J., Cheng, C.-Y., Yu, Y.W.-Y., Chen, T.-J., Hong, C.-J., 2003. Association study of a
brain-derived neurotrophic-factor genetic polymorphism and major depressive
disorders, symptomatology, and antidepressant response. Am. J. Med. Genet.
123B, 19–22, http://dx.doi.org/10.1002/ajmg.b.20026
Verhagen, M., van der Meij, A., van Deurzen, P.A.M., Janzing, J.G.E., Arias-Vásquez,
A., Buitelaar, J.K., Franke, B., 2008. Meta-analysis of the BDNF Val66Met poly-
morphism in major depressive disorder: effects of gender and ethnicity. Mol.
Psychiatry 15, 260–271, http://dx.doi.org/10.1038/mp.2008.109
Viechtbauer, W.,  Cheung, M.W.-L., 2010. Outlier and inﬂuence diagnostics for meta-








Zou, Y.-F., Ye, D.-Q., Feng, X.-L., Su, H., Pan, F.-M., Liao, F.-F., 2010. Meta-analysis of18 F. Harrisberger et al. / Neuroscience an
oineskos, A.N., Lerch, J.P., Felsky, D., Shaikh, S., Rajji, T.K., Miranda, D., Lobaugh,
N.J., Mulsant, B.H., Pollock, B.G., Kennedy, J.L., 2011. The brain-derived neu-
rotrophic factor Val66Met polymorphism and prediction of neural risk for
Alzheimer disease. Arch. Gen. Psychiatry 68, 198–206, http://dx.doi.org/10.
1001/archgenpsychiatry.2010.194
einstock-Guttman, B., Zivadinov, R., Taman˜o-Blanco, M.,  Abdelrahman, N., Bad-
gett, D., Durfee, J., Hussein, S., Feichter, J., Patrick, K., Benedict, R., Ramanathan,
M.,  2007. Immune cell BDNF secretion is associated with white matter volume in
multiple sclerosis. J. Neuroimmunol. 188, 167–174, http://dx.doi.org/10.1016/j.
jneuroim.2007.06.003
ells, G., Shea, B., O’Connell, D., Peterson, J., Welch, V., Losos, M.,  Tug-
well, P., 2014. The Newcastle-Ottawa Scale (NOS) for assessing the quality
of  nonrandomised studies in meta-analyses, 〈http://www.ohri.ca/programs/
clinical epidemiology/oxford.asp〉 (accessed 6.7.14) [WWW  Document].
olfgang Viechtbauer, 2010. Conducting meta-analyses in {R} with the {metafor}
package. J. Stat. Softw. 36, 1–48.
u, M.,  Li, S., Xing, Q., Gao, R., Feng, G., Lin, Z., St Clair, D., He, L., 2010. Genetic vari-
ants in the BDNF gene and therapeutic response to risperidone in schizophreniaehavioral Reviews 55 (2015) 107–118
patients: a pharmacogenetic study. Eur. J. Hum. Genet. 18, 707–712, http://dx.
doi.org/10.1038/ejhg.2009.238
Zai, G.C.M., Zai, C.C.H., Chowdhury, N.I., Tiwari, A.K., Souza, R.P., Lieberman, J.A.,
Meltzer, H.Y., Potkin, S.G., Müller, D.J., Kennedy, J.L., 2012. The role of brain-
derived neurotrophic factor (BDNF) gene variants in antipsychotic response and
antipsychotic-induced weight gain. Prog. Neuro-Psychopharmacol. Biol. Psychi-
atry 39, 96–101, http://dx.doi.org/10.1016/j.pnpbp.2012.05.014
Zivadinov, R., Weinstock-Guttman, B., Benedict, R., Taman˜o-Blanco, M.,  Hussein, S.,
Abdelrahman, N., Durfee, J., Ramanathan, M.,  2007. Preservation of gray mat-
ter volume in multiple sclerosis patients with the Met allele of the rs6265
(Val66Met) SNP of brain-derived neurotrophic factor. Hum. Mol. Genet. 16,BDNF Val66Met polymorphism association with treatment response in patients
with major depressive disorder. Eur. Neuropsychopharmacol. 20, 535–544,
http://dx.doi.org/10.1016/j.euroneuro.2009.12.005.
